13 completed, 4 recruiting, 2 active not recruiting, 2 not yet recruiting. 25 Phase 1, 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 25 | Completed 13, Recruiting 4, Active not recruiting 2, Not yet recruiting 2, Unknown 2, Withdrawn 2 |
| Phase 2 | 12 | Completed 5, Recruiting 4, Active not recruiting 2, Unknown 1 |
Follow Telangiectasis: new trials by email Literature Review of Telangiectasis trials Research Report on Telangiectasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Topical TOR-582 Treatment of Epistaxis in HHT Topical sirolimus ointment - Hereditary Hemorrhagic Telangiectasia (HHT), Epistaxis | Phase 1 | Not yet recruiting | Columbia University | 27 | 2027-03-01 | 2026-11-06 |
| Phase 1b Study of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT) TX002100 - Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 1 | Not yet recruiting | Tectonic Operating Company, Inc. | 20 | 2026-12-31 | 2026-10-15 |
| Safety and Efficacy of Mutation-targeted Precision Genetic Therapy for Ataxia-Telangiectasia (A-T) Antisense oligonucleotide targeting the ATM gene - Ataxia Telangiectasia | Phase 1 / Phase 2 | Recruiting | Timothy Yu | 10 | 2026-08-01 | 2026-05-28 |
| Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT) ATV-1601, Placebo - Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease | Phase 1 / Phase 2 | Recruiting | Atavistik Bio, Inc | 100 | 2026-07-27 | 2026-11-06 |
| DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia DIAG723, Placebo - Hereditary Hemorrhagic Telangiectasia, Pulmonary Arterial Hypertension | Phase 1 / Phase 2 | Recruiting | Diagonal Therapeutics, Inc. | 93 | 2026-06-04 | 2026-09-08 |
| A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia TER-1754, Placebo - Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 1 | Withdrawn | Terremoto Biosciences Inc. | 2025-12-15 | 2026-04-13 | |
| An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg - Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 / Phase 2 | Recruiting | Beijing Tide Pharmaceutical Co., Ltd | 266 | 2025-12-03 | 2026-01-28 |
| A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT) ALN-6400, Placebo - Hereditary Hemorrhagic Telangiectasia | Phase 1 / Phase 2 | Active not recruiting | Alnylam Pharmaceuticals | 89 | 2024-11-07 | 2026-10-15 |
| Pazopanib for the Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia Pazopanib - Hereditary Hemorrhagic Telangiectasia, Epistaxis | Phase 1 / Phase 2 | Unknown | Cure HHT | 30 | 2023-07-01 | 2022-09-08 |
| Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy Subjects GTX-102 medium dose fast Period 1 and Period 2, GTX-102 medium dose slow Period 1 and Period 2, GTX-102 high dose fast Period 1 and Period 2 - Ataxia Telangiectasia | Phase 1 | Unknown | Grace Therapeutics Inc. | 48 | 2022-09-13 | 2023-01-23 |
| Assess Safety and Efficacy of VAD044 in HHT Patients VAD044 Part I, VAD044 Part II - Hereditary Hemorrhagic Telangiectasia (HHT) | Phase 1 / Phase 2 | Active not recruiting | Vaderis Therapeutics AG | 75 | 2022-07-18 | 2026-03-17 |
| Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Elimusertib (BAY1895344), Pembrolizumab (Keytruda®) - Advanced Solid Tumors | Phase 1 | Completed | Bayer | 56 | 2019-09-30 | 2024-04-02 |
| MRA With Feraheme in HHT Feraheme MRI/MRA - Hereditary Hemorrhagic Telangiectasia | Phase 1 | Completed | University of California, Los Angeles | 10 | 2016-11-01 | 2019-01-25 |
| Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study Pomalidomide - Hereditary Hemorrhagic Telangiectasia, Idiopathic Vascular Ectasia | Phase 1 | Completed | The Cleveland Clinic | 9 | 2015-01-27 | 2020-07-15 |
| Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose bevacuzimab spray - Telangiectasia, Hereditary Hemorrhagic | Phase 1 / Phase 2 | Completed | University Hospital, Caen | 20 | 2014-12-15 | 2026-07-30 |
| Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept Topical timolol maleate, placebo saline drops - Hereditary Hemorrhagic Telangiectasia | Phase 1 / Phase 2 | Completed | Unity Health Toronto | 5 | 2013-05-01 | 2023-09-21 |
| The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in Hereditary Hemorrhagic Telangiectasia Bevacizumab - Rendu Osler Disease, Telangiectasia, Hereditary Hemorrhagic | Phase 1 | Completed | Hospices Civils de Lyon | 42 | 2011-10-01 | 2021-10-19 |
| Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT) Ranibizumab - Hereditary Hemorrhagic Telangiectasia (HHT), Nosebleeds | Phase 1 | Withdrawn | University of California, San Diego | 2011-07-01 | 2013-04-29 | |
| Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia Sclerotherapy, Standard Treatment - Epistaxis, Hereditary Hemorrhagic Telangiectasia | Phase 1 / Phase 2 | Completed | University of Minnesota | 18 | 2011-02-01 | 2019-11-01 |
| Combination Therapy for the Treatment of Rosacea calcium dobesilate, pulsed dye laser - Erythematotelangiectatic Rosacea | Phase 1 | Completed | Ellen Marmur | 6 | 2009-07-01 | 2019-06-17 |
Showing 20 of 25. Sign in to see all of them.
Telangiectasia, Hereditary Hemorrhagic (15) · Epistaxis (7) · Ataxia Telangiectasia (4) · Arteriovenous Malformations (3) · Vascular Malformations (3) · Idiopathic Juxtafoveal Retinal Telangiectasia (2) · Papilledema (2) · Rosacea (2) · Acne Vulgaris (1) · Anemia (1) · Carcinoma, Non-Small-Cell Lung (1) · Cardiovascular Diseases (1) · Disease (1) · Endometrial Neoplasms (1)
Cardiovascular Diseases (24) · Vascular Diseases (24) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (20) · Congenital Abnormalities (17) · Hemic and Lymphatic Diseases (16) · Cardiovascular Abnormalities (15) · Hematologic Diseases (15) · Hemorrhagic Disorders (15) · Hemostatic Disorders (15) · Vascular Malformations (12) · Pathological Conditions, Signs and Symptoms (10) · Pathologic Processes (9) · Respiratory Tract Diseases (9) · Signs and Symptoms (8)
Ranibizumab (5) · BAY 1895344 (1) · Bevacizumab (1) · Calcium Dobesilate (1) · Capsules (1) · Ferrosoferric Oxide (1) · Lasers, Dye (1) · Sclerotherapy (1) · Sodium Tetradecyl Sulfate (1) · Timolol (1) · pazopanib (1) · pembrolizumab (1) · pomalidomide (1) · pyratine 6 (1)
National Eye Institute (NEI) (2) · Alnylam Pharmaceuticals (1) · Atavistik Bio, Inc (1) · Bayer (1) · Beijing Tide Pharmaceutical Co., Ltd (1) · Columbia University (1) · Cure HHT (1) · Diagonal Therapeutics, Inc. (1) · Ellen Marmur (1) · Grace Therapeutics Inc. (1) · Hospices Civils de Lyon (1) · Johns Hopkins University (1) · Manhattan Eye, Ear & Throat Hospital (1) · Tectonic Operating Company, Inc. (1) · Terremoto Biosciences Inc. (1)
United States (16) · Canada (4) · France (3) · Spain (3) · Australia (2) · Germany (2) · Argentina (1) · Belgium (1) · China (1) · Italy (1) · Netherlands (1) · New Zealand (1) · Switzerland (1) · United Kingdom (1)
Christelle Achkar, MD (1) · Damien Picard (1) · Ellen Marmur, MD (1) · Gerald D Weinstein, MD (1) · Holly Boyer, MD (1) · Janice Faulknor, MD (1) · Justin McWilliams, MD (1) · Keith McCrae, MD (1) · Lawrence A. Yannuzzi, MD (1) · Marie E Faughnan, MD MSc FRCPC (1) · Neil M. Bressler, MD (1) · Raj Kasthuri, MD (1) · Terence Davidson, M.D. (1)
PMID 24481211, PMID 39510938, PMID 41297007
2018 (1), 2025 (1), U54NS065705 (1)